Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction
NCT ID: NCT03486080
Last Updated: 2021-05-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
49 participants
INTERVENTIONAL
2018-12-07
2021-02-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
NCT05881382
Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI
NCT04688723
The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
NCT01000727
A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
NCT00046228
Doxycycline to Protect Heart Muscle After Heart Attacks
NCT03508232
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary Objective
• To evaluate the safety and tolerability of dutogliptin in combination with filgrastim in subjects with STEMI compared with placebo
Secondary Objectives
* To assess preliminary efficacy of dutogliptin in combination with filgrastim in subjects with STEMI compared with placebo as determined by cardiac magnetic resonance imaging (cMRI)
* To determine the pharmacokinetics (PK) of dutogliptin in a subset of the study population
* To establish the pharmacodynamics (PD) of dutogliptin (plasma DPP4 activity) in a subset of the study population
Exploratory Objectives
* To examine the effects of dutogliptin in combination with filgrastim on:
* Change from baseline in plasma stromal cell-derived factor (SDF)-1a levels
* Change from baseline in plasma biomarkers, including N-terminal pro-b-type natriuretic peptide (NT-proBNP) and high sensitivity troponin
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dutogliptin/filgrastim combination
Twice daily SC injections of 60 mg dutogliptin tartrate for 14 days in combination with 10 µg/kg filgrastim injectable product for 5 days
Dutogliptin Tartrate
Active treatment
Filgrastim Injectable Product
Active treatment
Placebo control
Twice daily dutogliptin SC placebos for 14 days in combination with matching filgrastim SC placebos for 5 days
Placebos
placebo control
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dutogliptin Tartrate
Active treatment
Filgrastim Injectable Product
Active treatment
Placebos
placebo control
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Body weight \<96 kg (212 lb).
3. Able to provide written informed consent, including signing and dating the informed consent form (ICF).
4. Diagnosis of STEMI (defined as new ST-segment elevation at the J point of at least 2 continuous leads of \>2 mm \[0.2 mV\] in men or \>1.5 mm \[0.1 mV\] in women in leads V2 and V3 OR \>1 mm in any other contiguous precordial leads or the limb leads \[for both men and women\]) with PCI (bare metal or drug-eluting stent) and Thrombolysis in Myocardial Infarction flow grade 2 or 3 occurring \>2 hours and \<24 hours after symptom onset.
5. LVEF ≤45% obtained by cECHO performed within 36 hours post-stent placement.
6. Receiving standard medical therapy for post-MI treatment, according to local procedures and Principal Investigator discretion
7. Female subjects of childbearing potential must have a negative serum pregnancy test at Screening and an additional negative urine pregnancy test prior to the first dose of IMP unless regulated differently by national legislation.
8. Sexually active female subjects of childbearing potential (i.e., women who are not postmenopausal or who have not had a bilateral oophorectomy, hysterectomy, or tubal ligation) and all male subjects (who have not been surgically sterilized by vasectomy) must agree to use effective contraception during the study.
Exclusion Criteria
2. Complex peri/post-MI clinical course, including arrhythmias, cardiogenic shock, pulmonary edema requiring mechanical ventilation, or requirement for vasopressor medications.
3. Significant pre-existing cardiomyopathy with known LVEF ≤45% or moderate to severe mitral or aortic valvular disease.
4. Amyloidosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis.
5. Existing heart transplant.
6. Ventricular tachycardia or fibrillation not associated with an acute ischemic episode.
7. Uncontrolled hypertension (systolic \>180 mmHg or diastolic \>120 mmHg).
8. Treatment with any DPP4 inhibitors (e.g., alogliptin, linagliptin, vildagliptin, saxagliptin, sitagliptin) or G-CSF medication (e.g., filgrastim, lenograstim, pegfilgrastim, lipegfilgrastim) within 4 months prior to Randomization.
9. Contraindication to treatment with filgrastim, including known allergy to filgrastim or other G-CSF medication.
10. Anemia defined as hemoglobin \<9 g/dL prior to Randomization.
11. Thrombocytosis (platelets \>500 k/µL).
12. Known positive serology for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
13. Alanine aminotransferase (ALT) concentrations \>3 times the upper limit of normal (ULN) or bilirubin \>2 x ULN prior to Randomization, according to local laboratory assessments.
14. History of cirrhosis and Child-Pugh score B or C.
15. Current fever greater than 101.4 °F (38.6 °C) or recent systemic infection within 2 weeks prior to Randomization.
16. Contraindication to cMRI procedure, including prior implantable cardioverter defibrillator placement, known reaction to gadolinium, claustrophobia, non-MRI-compatible, cochlear implant, morbid obesity, or presence of ferromagnetic material including shunts, shrapnel, penile prostheses, or blood vessel coil.
17. Pregnant, planning to become pregnant, or nursing female subjects.
18. Autoimmune disease requiring immunosuppressive therapy or chronic steroid treatment \>5 mg/day prednisolone or equivalent.
19. Significant renal impairment defined as estimated glomerular filtration rate \<45 mL/min/1.73 m2, using the Chronic Kidney Disease Epidemiology Collaboration equation.
20. Active neoplasm requiring surgery, chemotherapy, or radiation within the prior 12 months (subjects with a history of malignancy who have undergone curative resection or otherwise not requiring treatment for at least 12 months prior to Screening with no detectable recurrence are allowed).
21. Malignant hematological disease, i.e., chronic myeloid leukemia or myelodysplastic syndrome.
22. History of cerebrovascular accident or transient ischemic attack in the past 6 months.
23. History of pneumonia in the last 4 weeks.
24. History of any significant medical or psychiatric disorder that in the opinion of the investigator would make the subject unsuitable for participation in the study.
25. Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) or treatment with an investigational biologic drug within 6 weeks prior to randomization.
26. Participation in another concurrent clinical trial involving a therapeutic intervention (participation in observational studies and/or registry studies is permitted).
27. Unable or unwilling to comply with the requirements of the study.
28. Subject and/or an immediate family member is an employee of the investigational site directly affiliated with this study, the sponsor or the contract research organization.
29. Considered by the investigator to be unsuitable to participate in the study for any other reason.
30. Persons who are in an institution as a result of an administrative or judicial order, or soldiers.
31. History of alcohol or drug abuse.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Recardio, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roman Schenk, MD
Role: STUDY_CHAIR
Recardio, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical department of Cardiology
Graz, , Austria
Klinikum Klagenfurt am Wörthersee
Klagenfurt, , Austria
Algemeen Stedelijk Ziekenhuis Aalst
Aalst, , Belgium
Military Hospital
Budapest, , Hungary
Semmelweis Egyetem Városmajori Szív- és Érgyógyászati Klinika
Budapest, , Hungary
Debreceni Egyetem Kardiológiai és Szívsebészeti Klinika
Debrecen, , Hungary
Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház
Miskolc, , Hungary
Maasstad Ziekenhuis
Rotterdam, , Netherlands
Nicolaus Copernicus University
Bydgoszcz, , Poland
SPS Szpital Zachodni
Grodzisk Mazowiecki, , Poland
Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi ul. Pomorska 251
Lodz, , Poland
Samodzielny Publiczny Szpital Wojewódzki im. Papieża Jana Pawła II
Zamość, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Recardio, Inc. Homepage
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REC-DUT-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.